Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Satellos Bioscience Inc.

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Participation in September 2024 Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Q2 2024 Financial Results and Updated Canine Data
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Present at Upcoming Virtual Investor Conferences in March and April
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Recognized as a Top 50 TSX Venture Exchange Company
From Satellos Bioscience Inc.
Via Business Wire
Tickers TSX:MSCL
Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Commence Trading on the Toronto Stock Exchange
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
Satellos Bioscience Announces 2023 Q3 Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Tickers TSX-V:MSCL
Satellos to Present at the Piper Sandler 35th Annual Healthcare Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
Satellos to Present at the Stifel 2023 Healthcare Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.